|
Dr John Baker is our current Clinical & Executive Director – a position he has successfully held for some years. Under John’s stewardship our organisation has become streamlined, effective and efficient and the Middlemore Clinical Trials Board could not be more proud of his achievements. Recently, John signalled that he would like to begin planning towards retirement. The Board has considered Middlemore Clinical Trials' structure and determined that John’s current role can be divided into two: Clinical Director and CEO. This will ensure MMCT continues to run smoothly and meets the needs of Investigators, Sponsors and MMCT Staff, and is more representative of the future vision of Middlemore Clinical Trials’ Board of Trustees.
The Middlemore Clinical Trials’ Board is now actively seeking a full time CEO. John will assist the new CEO transition into the organisation. Once that has occurred, John will step into a dedicated Clinical Director role effective 1st January 2019, which includes retaining his Principal Investigator responsibilities for the Diabetes trial portfolio over the coming years.
There will be no impact on business/trials over the coming months as John will continue in his current role until the new CEO starts, will be pivotal in ensuring a smooth handover to the new CEO, and will stay on with us as Clinical Director and as an active investigator.
TOP
|